Inozyme Pharma
(NASDAQ) INZY
This security has been delisted. This page is retained for historical reference.
INZY News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowINZY Financials
Key Financial Metrics (TTM)
Gross Margin
0.00%
Operating Margin
0.00%
Net Income Margin
0.00%
Return on Equity
-102.90%
Return on Capital
-99.36%
Return on Assets
-82.82%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$0.00
Operating Income
-$107.38M
EBITDA
-$100.34M
Operating Cash Flow
-$96.52M
Capital Expenditure
-$30.00K
Free Cash Flow
-$96.55M
Cash & ST Invst.
$84.78M
Total Debt
$46.95M
Inozyme Pharma Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$0.00
N/A
Gross Margin
0.00%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
67
N/A
Net Income
-$28.04M
-20.1%
EBITDA
-$26.46M
-21.1%
Quarterly Fundamentals
Total Cash
$84.78M
-49.0%
Total Debt
$46.95M
+0.7%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$20.59M
-55.0%
Short Term Debt
$26.37M
+1311.6%
Return on Assets
-82.82%
N/A
Return on Invested Capital
-1.17%
N/A
Free Cash Flow
-$29.15M
-18.7%
Operating Cash Flow
-$29.15M
-18.8%